All In Biotech

Drug Trial Radar · NCT06367465

Feasibility and Acceptability of HCV Treatment in Pregnancy

Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 1, 2024

Primary completion

Dec 28, 2026

Study completion Dec 28, 2026

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years

Summary

As written by the sponsor on the registry.

Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year. Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.

Conditions

  • Hepatitis C
  • Pregnancy Complications

Interventions

  • Glecaprevir-pibrentasvirDrug

    Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medication adherence and treatment completion rates.Time frame: 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Barnes Jewish Hospital

    St Louis, Missouri · Recruiting

  • Washington Univeristy

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.